Status:
RECRUITING
Real-World Study of DLBCL With Different Genetic Subtypes
Lead Sponsor:
Ruijin Hospital
Conditions:
DLBCL - Diffuse Large B Cell Lymphoma
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
Detailed Description
DLBCL is a highly common malignant tumor in Asia. The aim of the study is to observe and explore the clinical information on DLBCL patients with different genetic subtypes and to analyze the clinical ...
Eligibility Criteria
Inclusion
- Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
- Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others
- Fully comprehension and signature of the informed consent form (ICF) for participation
Exclusion
- Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period
- Severe mental illness
- Patients deemed unsuitable for inclusion by the investigator
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT06026488
Start Date
October 1 2023
End Date
December 31 2026
Last Update
December 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025